Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic
With Series C, Start-Up Has Raised $213.5m To Date
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.
